Icecure Medical Ltd ICCM

NAS: ICCM | ISIN: IL0011224156   8/07/2025
1,148 USD (+9,36%)
(+9,36%)   8/07/2025
Grafiek Icecure Medical Ltd Grafiek Icecure Medical Ltd

Icecure Medical Ltd in het nieuws

6 mei 2025 · IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation · Persbericht

30 april 2025 · IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer · Persbericht

28 april 2025 · IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium · Persbericht

22 april 2025 · IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation · Persbericht

27 maart 2025 · IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America · Persbericht

24 maart 2025 · IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate · Persbericht

21 maart 2025 · IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 · Persbericht

20 maart 2025 · IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer · Persbericht

18 maart 2025 · IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference · Persbericht

17 maart 2025 · IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology · Persbericht

Mijn selecties